Human Feedback Types
partialPairwise Preference
Directly usable for protocol triage.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
HFEPX · Eval paper review
Jiangjie Qiu, Chengrui Xu, Xiaonan Wang
Published
Nov 21, 2026
Citations
0
Trust level
Low
Usefulness score
40/100 (Low)
Extraction confidence
45% (Low)
Derived from extracted protocol signals and abstract evidence.
Rater population
Not reported
Signals refreshed
Nov 21, 2026
This paper is adjacent to HFEPX scope and is best used for background context, not as a primary protocol reference.
Use this as background context only. Do not make protocol decisions from this page alone.
Use this page for context, then validate protocol choices against stronger HFEPX references before implementation decisions.
Best use
Background context only
Use if you need
Background context only.
What to verify
Read the full paper before copying any benchmark, metric, or protocol choices.
Main weakness
The available metadata is too thin to trust this as a primary source.
Treat as adjacent context, not a core eval-method reference.
If you are doing eval pipeline work, start here
Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.
These are the protocol signals we could actually recover from the available paper metadata. Use them to decide whether this paper is worth deeper reading.
Pairwise Preference
Directly usable for protocol triage.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
None explicit
Validate eval design from full paper text.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
Not reported
No explicit QC controls found.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
Not extracted
No benchmark anchors detected.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
Not extracted
No metric anchors detected.
"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."
No benchmark or dataset names were extracted from the available abstract.
No metric terms were extracted from the available abstract.
Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing.
Based on abstract + metadata only. Check the source paper before making high-confidence protocol decisions.
Human feedback protocol is explicit
Detected: Pairwise Preference
Evaluation mode is explicit
No clear evaluation mode extracted.
Quality control reporting appears
No calibration/adjudication/IAA control explicitly detected.
Benchmark or dataset anchors are present
No benchmark/dataset anchor extracted from abstract.
Metric reporting is present
No metric terms extracted.